Every 10-Q that Cronos Group Inc. (CRON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRON filings page.
Cronos Group Inc., a global cannabis company, reported markedly stronger Q2 2026 results. Net revenue was $53,007 versus $33,455 a year earlier, with gross profit of $28,451 and operating income of $7,404 versus a prior operating loss. Net income attributable to Cronos Group was $32,085 compared with a loss in Q2 2025, helped by higher cannabis flower and extract sales and a foreign currency gain of $20,219.
For the first six months of 2026, net revenue rose to $98,217 and operating income to $5,571, with Adjusted EBITDA improving to $18,167 from $3,977. Q2 Adjusted EBITDA reached $13,088, while restructuring costs fell to $308. Canada and Israel remained the largest markets.
Liquidity stayed very strong: cash and cash equivalents, short-term investments and non‑current interest-bearing deposits totaled $827,019 against total liabilities of $62,415 as of June 30, 2026. The company repurchased 12,253,870 shares for $32,858 year‑to‑date and authorized a new share repurchase program of up to $50,000, with open‑market buybacks capped at 18,712,918 shares. A proposed $10,000,000 settlement of a U.S. securities class action is pending final court approval, and new anti‑dumping investigations in Israel could affect future imports. Two major customers accounted for 44% of Q2 net revenue before excise taxes.
Cronos Group Inc. reported significantly stronger results for the quarter ended March 31, 2026. Net revenue rose to 45,210 (thousands of U.S. dollars) from 32,262 a year earlier, driven by cannabis flower and extracts in Canada and Israel. Net income attributable to Cronos increased to 13,752, with basic and diluted EPS of 0.04 versus 0.02. Adjusted EBITDA improved to 5,079 from 2,289, reflecting higher gross profit despite ongoing restructuring and transaction costs. The company ended the quarter with 821,856 in cash and cash equivalents and no debt, after repurchasing 6,365,700 common shares for 16,730 under its 50,000 share repurchase authorization. A new 50,000 repurchase program was approved to follow the current one, and Cronos continues to pursue the pending acquisition of CanAdelaar and manage legal and regulatory matters, including a proposed 10,000 class action settlement that remains subject to court approval.
Cronos Group Inc. reported stronger Q3 results. For the three months ended September 30, 2025, net revenue was $36.3 million versus $34.3 million a year ago, led by cannabis flower $26.4 million and extracts $10.0 million. Gross profit rose to $18.3 million from $3.6 million as cost of sales declined.
Operating loss narrowed to $0.5 million from $33.7 million. Total other income was $27.5 million, including a foreign currency gain of $19.8 million and a $4.1 million gain on revaluation of financial instruments, partly offset by a $3.0 million loss on held-for-sale assets and a $4.8 million change in allowance for credit loss on a non-operating loan. Net income attributable to Cronos Group was $26.0 million ($0.07 per diluted share), up from $8.3 million ($0.02) in the prior-year quarter.
Cash and cash equivalents were $784.2 million with $40.0 million of short-term investments. Total assets were $1.178 billion against total liabilities of $46.4 million. Year-to-date, operating activities provided $14.0 million of cash, while investing used $79.3 million and financing used $12.5 million. Canada contributed $23.1 million of quarterly revenue and Israel $11.4 million. Shares outstanding were 382,893,267 as of November 3, 2025.